Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2

Zhang, Panli; Luo, Songyuan; Zou, Peng; Liang, Chun-Ling; Li, Jinfeng; Li, Yongyin; Wang, Gang; Zhang, Ling; Li, Tingting; Li, Chengyao

doi:10.1016/j.omtm.2022.06.011

Cited by 2 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we utilized a novel simian adenovirus 23 vectored COVID-19 vaccine (Sad23L-nCoV-S) with low pre-existing immunity in humans to evaluate the effects of systemic and local mucosal immunity in mice by different immunization regimens via IN and IM routes. The superior immunogenicity of adenovirus-vectored vaccine has been previously demonstrated by IM injection ( 23 , 24 ). As shown in Fig.…”

Section: Discussionmentioning

confidence: 95%

“…Pseudoviruses expressing SARS-CoV-2 S protein of Wild-type (Wuhan-1) strain, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), or Omicron (B.1.1.529) variants were generated, and the neutralizing antibody (NAb) to SARS-CoV-2 was measured by pseudovirus neutralization test (pVNT) ( 24 ). Briefly, the psPAX2 (Addgene), pLenti-CMV Puro-Luc (Addgene), and pcDNA3.1-SARS-CoV-2 S plasmids were co-transfected into HEK-293T cells.…”

Section: Methodsmentioning

confidence: 99%

“…We have previously developed a COVID-19 vaccine (Sad23L-nCoV-S) based on a simian adenovirus type 23 vector (Sad23L) carrying the full-length S gene of SARS-CoV-2 ( 23 ). Our previous studies have shown that IM inoculation with this vaccine elicited strong humoral and cellular immune responses in C57BL/6 and BALB/C mice, cats, and rhesus monkeys ( 23 , 24 ). The combination of IM and IN inoculations, which induce the durable systemic IgG, local mucosal antibodies and memory T cells, ultimately leads to a long-lasting protective immunity, achieving that the whole is greater than the sum of its parts, most likely one of the ideal vaccination strategies for obtaining prolonged immunity ( 25 ).…”

Section: Introductionmentioning

confidence: 91%

See 2 more Smart Citations

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

Zhang,

Luo,

Zou

et al. 2023

Microbiol Spectr

Self Cite

View full text Add to dashboard Cite

The failure of COVID-19 vaccines to prevent SARS-CoV-2 infection and transmission, a possibly critical reason was the lack of protective mucosal immunity in the respiratory tract. Here, we evaluated the effects of mucosal and systemic immunity from a novel simian adenovirus-vectored COVID-19 vaccine (Sad23L-nCoV-S) in mice in comparison with Ad5-nCoV-S by intranasal (IN) drip and intramuscular (IM) injection vaccinations. As good as the well-known Ad5-nCoV-S vaccine, a single-dose IN inoculation of 1 × 10 9 PFU Sad23L-nCoV-S vaccine induced a similar level of IgG S-binding antibody (S-BAb) and neutralizing antibody (NAb) and higher IgA in serum, while IN route raised significantly higher IgG and IgA S-BAb and NAb in bronchoalveolar lavage (BAL), and specific IFN-γ secreting T-cell response in lung compared with IM route, but lower T-cell response in spleen. By prime-boost vaccination regimens with different combinations of IN and IM inoculations of Sad23L-nCoV-S vaccine, the IN-involved vaccination stimulated higher protective mucosal or local immunity in BAL and lung, while the IM-involved immunization induced higher systemic immunity in serum and spleen. A long-term sustained mucosal and systemic NAb and T- cell immunity to SARS-CoV-2 was maintained at high level over 32 weeks by prime-boost vaccination regimens with IN and IM routes. In conclusion, priming or boosting immunization with IN inoculation of Sad23L-nCoV-S vaccine could induce effective mucosal immunity and in combination of IM route could additionally achieve systemic immunity, which provided an important reference for vaccination regimens against respiratory virus infection. IMPORTANCE The essential goal of vaccination is to generate potent and long-term protection against diseases. Several factors including vaccine vector, delivery route, and boosting regimen influence the outcome of prime-boost immunization approaches. The immunization regimens by constructing a novel simian adenovirus-vectored COVID-19 vaccine and employing combination of intranasal and intramuscular inoculations could elicit mucosal neutralizing antibodies against five mutant strains in the respiratory tract and strong systemic immunity. Immune protection could last for more than 32 weeks. Vectored vaccine construction and immunization regimens have positively impacted respiratory disease prevention.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

See 1 more Smart Citation

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

Zhang,

Luo,

Zou

et al. 2023

Microbiol Spectr

Self Cite

View full text Add to dashboard Cite

show abstract

“…The copyright holder for this preprint (which this version posted April 19, 2023. ; https://doi.org/10.1101/2023.04.17.537220 doi: bioRxiv preprint measured by pseudovirus neutralization test (pVNT) (24). Briefly, the psPAX2 (Addgene), pLenti-CMV Puro-Luc (Addgene), and pcDNA3.1-SARS-CoV-2 S plasmids were co-transfected into HEK-293T cells.…”

Section: Pseudovirus Neutralization Testmentioning

confidence: 99%

“…We have previously developed a COVID-19 vaccine (Sad23L-nCoV-S) based on a simian adenovirus type 23 vector (Sad23L) carrying the full-length S gene of SARS-CoV-2 (23). Our previous studies have shown that IM inoculation of this vaccine elicited strong humoral and cellular immune responses in C57BL/6 and BALB/C mice, cats and rhesus monkeys (23,24). The combination of IM and IN inoculations, which induces the durable systemic IgG, local mucosal antibodies and was not certified by peer review) is the author/funder.…”

Section: Introductionmentioning

confidence: 99%

A novel simian adenovirus vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

Zhang

Luo

Zou³

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The failure of COVID-19 vaccines to prevent SARS-CoV-2 infection and transmission, a possibly critical reason was the lack of protective mucosal immunity in respiratory tract. Here, we evaluated the effects of mucosal and systemic immunity from a novel simian adenovirus vectored COVID-19 vaccine (Sad23L-nCoV-S) in mice in comparison with Ad5-nCoV-S by intranasal (IN) drip and intramuscular (IM) injection vaccinations. As good as the well-known Ad5-nCoV-S vaccine, a single-dose IN inoculation of 1×109PFU Sad23L-nCoV-S vaccine induced a similar level of IgG S-binding antibody (S-BAb) and neutralizing antibody (NAb) and higher IgA in serum, while IN route raised significantly higher IgG and IgA S-BAb and NAb in bronchoalveolar lavage (BAL), and specific IFN-γ secreting T cell response in lung compared with IM route, but lower T cell response in spleen. By prime-boost vaccination regimens with different combination of IN and IM inoculations of Sad23L-nCoV-S vaccine, the IN involved vaccinations stimulated higher protective mucosal or local immunity in BAL and lung, while the IM involved immunizations induced higher systemic immunity in serum and spleen. A long-term sustained systemic and mucosal NAb and T cell immunity to SARS-CoV-2 was maintained at high levels over 32 weeks by prime-boost vaccination regimens with IN and IM routes. In conclusion, priming or boosting immunization with IN inoculation of Sad23L-nCoV-S vaccine could induced effective mucosal immunity and in combination of IM route could additionally achieve systemic immunity, which provided an important reference for vaccination regimens against respiratory virus infection

show abstract

Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2

Cited by 2 publications

References 31 publications

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

A novel simian adenovirus vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens

Contact Info

Product

Resources

About